Skip to Main Content

Author Details

Neil E Bhola
Zai Lab (US) LLC
2006
41
24
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37663435Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor.Cancer Res Commun2023
36052495Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
36052496Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
34261774Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2021
34546978Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.JCI Insight2021
34591642A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.Science2021
34346116PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.Head Neck2021
34363390Corrigendum to: The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells.Carcinogenesis2021
31914141Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.PLoS One2020
30683736Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer.J Exp Med2019
31345392ATR inhibition sensitizes HPV<sup>-</sup> and HPV<sup>+</sup> head and neck squamous cell carcinoma to cisplatin.Oral Oncol2019
31219154The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells.Carcinogenesis2019
30770492Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer.Clin Cancer Res2019
30770371Correction: Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer.Cancer Res2019
30770369Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.Cancer Res2019
30770370Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.Cancer Res2019
29792310BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.Cancer Res2018
29440171Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2018
27986750Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2017
28249908Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.Cancer Res2017
28566428Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers.Sci Transl Med2017
28751448Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer.Clin Cancer Res2017
27370607HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.Clin Cancer Res2016
26676751Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.Cancer Res2016
27868025A sensible approach to targeting STAT3-mediated transcription.Ann Transl Med2016
25480943Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.Cancer Res2015
26235139Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.Cancer Lett2015
25953087Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.Mol Cell Proteomics2015
23204226Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.Cancer Res2013
23966295Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.Cancer Res2013
23391723TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.J Clin Invest2013
22491800Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.Mol Cancer Ther2012
22683778Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.Nat Med2012
21653688Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab.Clin Cancer Res2011
20388852Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.Clin Cancer Res2010
20426488Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.J Proteome Res2010
19798668Systematic prediction of human membrane receptor interactions.Proteomics2009
17981673Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer.Front Biosci2008
19074839Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.Mol Cancer Res2008
17431120Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.Mol Cancer Ther2007
17178880Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.Cancer Res2006
  • 1 - 41 of 41

Recommended Authors

Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 1
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Luping Lin
Incyte Research Institute, Incyte Corporation
Career Start Year 2010
Number of shared co-authors 4
Katherine R Singleton
Duke University
Career Start Year 2009
Number of shared co-authors 2
Juan L Callejas-Valera
Cancer Biology Research Center
Career Start Year 2008
Number of shared co-authors 3
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 3
Gabi Tarcic
Hadassah Ein-Kerem Medical Center Campus
Career Start Year 2004
Number of shared co-authors 10
Jalna Meens
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 0
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 0
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 3
Justin Cidado
Oncology R&D
Career Start Year 2003
Number of shared co-authors 1
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 6
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2002
Number of shared co-authors 1
Wei Shi
Research Institute, Princess Margaret Cancer Centre
Career Start Year 2002
Number of shared co-authors 1
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 1
Eddy S Yang
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 11
Mitchell J Frederick
Baylor College of Medicine
Career Start Year 1995
Number of shared co-authors 4
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 0
Mark M Moasser
Helen Diller Family Comprehensive Cancer Center
Career Start Year 1994
Number of shared co-authors 6
Ron Bose
Washington University School of Medicine
Career Start Year 1991
Number of shared co-authors 3
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 9
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 3
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 5
Lori S Hart
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 0
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 3
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 3

Collaborators

Jennifer R Grandis
University of California san francisco
Co-authored papers 26
Daniel E Johnson
University of California San Francisco
Co-authored papers 12
Hua Li
University of California san francisco
Co-authored papers 9
Yan Zeng
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College
Co-authored papers 8
Melinda E Sanders
Co-authored papers 8
Rachel A O'Keefe
University of California San Francisco
Co-authored papers 7
Justin M Balko
Co-authored papers 7
Umamaheswar Duvvuri
University of Pittsburgh School of Medicine
Co-authored papers 7
Toni M Brand
University of Wisconsin School of Medicine and Public Health
Co-authored papers 7
Stefan Hartmann
University Hospital Wurzburg
Co-authored papers 6
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Co-authored papers 5
Max V Ranall
University of California San Francisco
Co-authored papers 5
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 5
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 5
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 5
Julie E Bauman
George Washington University
Co-authored papers 4
Margaret Soucheray
J. David Gladstone Institutes
Co-authored papers 4
Ingrid A Mayer
Vanderbilt University Medical Center
Co-authored papers 4
Michelle A Ozbun
The University of New Mexico School of Medicine
Co-authored papers 3
Thomas Stricker
Co-authored papers 3
Carolyn Kemp
University of Pittsburgh Medical Center, Eye and Ear Institute
Co-authored papers 3
Raja R Seethala
University of Pittsburgh Medical Center-Presbyterian
Co-authored papers 2
Mehdi Bouhaddou
J. David Gladstone Institutes
Co-authored papers 2
Danielle L Swaney
J. David Gladstone Institutes
Co-authored papers 2
Mi-Ok Kim
University of California san francisco
Co-authored papers 2
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 2
Scott R VandenBerg
University of California san francisco
Co-authored papers 2
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 2
Paula I Gonzalez-Ericsson
Co-authored papers 2
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 1
Release 1.2